Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of psychedelic substances. Further, experts believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications associated with the COVID-19 pandemic.
To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this link
The over USD 6.5 billion (by 2030) financial opportunity within the psychedelic therapeutics market has been analyzed across the following segments:
- Target Disease Indication
- Anxiety and Depression
- Trauma
- Pain Disorder
- Sleep related Disorder
- Origin of Psychedelic Substance
- Natural
- Synthetic
- Type of Psychedelic Substance
- Gamma-hydroxybutyrate
- Ketamine
- MDMA
- Psilocybin
- Route of Administration
- Oral
- Intranasal
- Sublingual
- Key Geographies
- North America
- Europe
- Asia-Pacific
The Global Psychedelic Therapeutics Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Celon Pharma
- iX Biopharma
- MAPS Public Benefit
- MindMed
- Janssen Pharmaceuticals
- Jazz Pharmaceutical
Table of Contents
- Preface
2. Executive Summary
Introduction
- Market Landscape: Psychedelic Therapeutics
- Company Profiles
- Clinical Trial Analysis
- Clinical Trial Site Analysis
- Key Opinion Leader (KOL) Analysis
- Academic Grants Analysis
- Partnerships and Collaborations
- Mergers and Acquisitions
- Market Forecast and Opportunity Analysis
- Concluding Remarks
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Report Keywords - Next Generation, Inhibitors, Stimulators Market, Roots Analysis, Report Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade.
It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators.
A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators.Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products).An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.An analysis of the partnerships that have been established in this domain, in the recent past.A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.An analysis of the initiatives of big biopharma players engaged in this domain.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) To request for sample report – https://www.rootsanalysis.com/reports/303/request-sample.html Target Disease Indication Breast CancerChronic Lymphocytic LeukemiaColorectal CancerHead and Neck CancerLung CancerLupus NephritisMelanomaMultiple MyelomaPrimary Sjögren's SyndromeOthers Target Immune CheckpointB7-H3CD38CD40CD47OthersMechanism of ActionInhibitoryStimulatoryTherapeutic ModalityMonoclonal AntibodySmall MoleculeType of Therapy Monotherapy Combination TherapyRoute of AdministrationIntravenousSubcutaneousOthersKey Geographical Region North AmericaEuropeAsia-Pacific and the Rest of the World Key companies covered in the reportBristol Myers SquibbGlaxoSmithKlineIncyteNovartisTrillium Therapeutics For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html Other Recent OfferingsNeoantigen Targeted Therapies Market, 2019-2030Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] - https://www.facebook.com/RootsAnalysisLinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/Twitter - https://twitter.com/RootsAnalysis
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment London Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings.
Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.
Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics.
Europe is currently regarded as a key manufacturing hub for microbial biologicsThere are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%).
On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel.
Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%).
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
The global Hydrazine Hydrate Market was valued at USD 395.7 Million in 2016 and is projected to reach USD 531.1 Million by 2022, at a CAGR of 5.5% from 2017 to 2022.Browse 147 Market Data Tables and 36 Figures spread through 159 Pages and in-depth TOC on "Hydrazine Hydrate Market”.Polymerization & blowing agents is estimated to be the largest application segment of the global hydrazine hydrate market between 2017 and 2022Among various applications, polymerization & blowing agents is estimated to be the largest application of the global hydrazine hydrate market.
In addition, there are several other hydrazine-based chemical blowing agents such as benzene and toluenesulfonylhydrazide, which are used in low temperature applications.Speak to our analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=172748863New product launch was the key strategy adopted by major players to enhance their presence in the global hydrazine hydrate market between 2014 and 2016.
This strategy accounted for a major share of all development strategies adopted by leading players during the above-mentioned period.
The company operates through three business segments, namely, high performance materials, industrial specialties, and coating solutions.
The company has a widespread presence and distribution networks in Asia Pacific, Europe, Middle East & Africa, and the Americas.Lonza is also one of the major producers of hydrazine hydrate and supplies various concentration grades such as 35%, 51.2%, 54.4%, 64%, 98%, and 99%.
It operates its business through two segments namely, Pharma and Specialty Ingredients segments.
